These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

485 related articles for article (PubMed ID: 30355031)

  • 1. In Vivo Ryr2 Editing Corrects Catecholaminergic Polymorphic Ventricular Tachycardia.
    Pan X; Philippen L; Lahiri SK; Lee C; Park SH; Word TA; Li N; Jarrett KE; Gupta R; Reynolds JO; Lin J; Bao G; Lagor WR; Wehrens XHT
    Circ Res; 2018 Sep; 123(8):953-963. PubMed ID: 30355031
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term efficacy and safety of cardiac genome editing for catecholaminergic polymorphic ventricular tachycardia.
    Moore OM; Aguilar-Sanchez Y; Lahiri SK; Hulsurkar MM; Alberto Navarro-Garcia J; Word TA; Keefe JA; Barazi D; Munivez EM; Moore CT; Parthasarathy V; Davidson J; Lagor WR; Park SH; Bao G; Miyake CY; Wehrens XHT
    J Cardiovasc Aging; 2024 Jan; 4(1):. PubMed ID: 38464671
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sudden infant death syndrome in mice with an inherited mutation in RyR2.
    Mathur N; Sood S; Wang S; van Oort RJ; Sarma S; Li N; Skapura DG; Bayle JH; Valderrábano M; Wehrens XH
    Circ Arrhythm Electrophysiol; 2009 Dec; 2(6):677-85. PubMed ID: 20009080
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Calcium signaling consequences of RyR2 mutations associated with CPVT1 introduced via CRISPR/Cas9 gene editing in human-induced pluripotent stem cell-derived cardiomyocytes: Comparison of RyR2-R420Q, F2483I, and Q4201R.
    Zhang XH; Wei H; Xia Y; Morad M
    Heart Rhythm; 2021 Feb; 18(2):250-260. PubMed ID: 32931925
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mice with the R176Q cardiac ryanodine receptor mutation exhibit catecholamine-induced ventricular tachycardia and cardiomyopathy.
    Kannankeril PJ; Mitchell BM; Goonasekera SA; Chelu MG; Zhang W; Sood S; Kearney DL; Danila CI; De Biasi M; Wehrens XH; Pautler RG; Roden DM; Taffet GE; Dirksen RT; Anderson ME; Hamilton SL
    Proc Natl Acad Sci U S A; 2006 Aug; 103(32):12179-84. PubMed ID: 16873551
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of catecholaminergic polymorphic ventricular tachycardia in mice using novel RyR2-modifying drugs.
    Li N; Wang Q; Sibrian-Vazquez M; Klipp RC; Reynolds JO; Word TA; Scott L; Salama G; Strongin RM; Abramson JJ; Wehrens XHT
    Int J Cardiol; 2017 Jan; 227():668-673. PubMed ID: 27838126
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Paradoxical effect of increased diastolic Ca(2+) release and decreased sinoatrial node activity in a mouse model of catecholaminergic polymorphic ventricular tachycardia.
    Neco P; Torrente AG; Mesirca P; Zorio E; Liu N; Priori SG; Napolitano C; Richard S; Benitah JP; Mangoni ME; Gómez AM
    Circulation; 2012 Jul; 126(4):392-401. PubMed ID: 22711277
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In situ confocal imaging in intact heart reveals stress-induced Ca(2+) release variability in a murine catecholaminergic polymorphic ventricular tachycardia model of type 2 ryanodine receptor(R4496C+/-) mutation.
    Chen B; Guo A; Gao Z; Wei S; Xie YP; Chen SR; Anderson ME; Song LS
    Circ Arrhythm Electrophysiol; 2012 Aug; 5(4):841-9. PubMed ID: 22722659
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EL20, a potent antiarrhythmic compound, selectively inhibits calmodulin-deficient ryanodine receptor type 2.
    Klipp RC; Li N; Wang Q; Word TA; Sibrian-Vazquez M; Strongin RM; Wehrens XHT; Abramson JJ
    Heart Rhythm; 2018 Apr; 15(4):578-586. PubMed ID: 29248564
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gene Transfer of Engineered Calmodulin Alleviates Ventricular Arrhythmias in a Calsequestrin-Associated Mouse Model of Catecholaminergic Polymorphic Ventricular Tachycardia.
    Liu B; Walton SD; Ho HT; Belevych AE; Tikunova SB; Bonilla I; Shettigar V; Knollmann BC; Priori SG; Volpe P; Radwański PB; Davis JP; Györke S
    J Am Heart Assoc; 2018 May; 7(10):. PubMed ID: 29720499
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Catecholaminergic polymorphic ventricular tachycardia is caused by mutation-linked defective conformational regulation of the ryanodine receptor.
    Uchinoumi H; Yano M; Suetomi T; Ono M; Xu X; Tateishi H; Oda T; Okuda S; Doi M; Kobayashi S; Yamamoto T; Ikeda Y; Ohkusa T; Ikemoto N; Matsuzaki M
    Circ Res; 2010 Apr; 106(8):1413-24. PubMed ID: 20224043
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased Ca2+ sensitivity of the ryanodine receptor mutant RyR2R4496C underlies catecholaminergic polymorphic ventricular tachycardia.
    Fernández-Velasco M; Rueda A; Rizzi N; Benitah JP; Colombi B; Napolitano C; Priori SG; Richard S; Gómez AM
    Circ Res; 2009 Jan; 104(2):201-9, 12p following 209. PubMed ID: 19096022
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heterogeneity of ryanodine receptor dysfunction in a mouse model of catecholaminergic polymorphic ventricular tachycardia.
    Loaiza R; Benkusky NA; Powers PP; Hacker T; Noujaim S; Ackerman MJ; Jalife J; Valdivia HH
    Circ Res; 2013 Jan; 112(2):298-308. PubMed ID: 23152493
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Calcium leak through ryanodine receptors leads to atrial fibrillation in 3 mouse models of catecholaminergic polymorphic ventricular tachycardia.
    Shan J; Xie W; Betzenhauser M; Reiken S; Chen BX; Wronska A; Marks AR
    Circ Res; 2012 Aug; 111(6):708-17. PubMed ID: 22828895
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In Vivo Genome Editing Restores Dystrophin Expression and Cardiac Function in Dystrophic Mice.
    El Refaey M; Xu L; Gao Y; Canan BD; Adesanya TMA; Warner SC; Akagi K; Symer DE; Mohler PJ; Ma J; Janssen PML; Han R
    Circ Res; 2017 Sep; 121(8):923-929. PubMed ID: 28790199
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gene Therapy for Catecholaminergic Polymorphic Ventricular Tachycardia by Inhibition of Ca
    Bezzerides VJ; Caballero A; Wang S; Ai Y; Hylind RJ; Lu F; Heims-Waldron DA; Chambers KD; Zhang D; Abrams DJ; Pu WT
    Circulation; 2019 Jul; 140(5):405-419. PubMed ID: 31155924
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Allele-Specific Silencing of Mutant mRNA Rescues Ultrastructural and Arrhythmic Phenotype in Mice Carriers of the R4496C Mutation in the Ryanodine Receptor Gene (
    Bongianino R; Denegri M; Mazzanti A; Lodola F; Vollero A; Boncompagni S; Fasciano S; Rizzo G; Mangione D; Barbaro S; Di Fonso A; Napolitano C; Auricchio A; Protasi F; Priori SG
    Circ Res; 2017 Aug; 121(5):525-536. PubMed ID: 28620067
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Description of a novel RyR2 mutation in a juvenile patient with symptomatic catecholaminergic polymorphic ventricular tachycardia in sleep and during exercise: a case report.
    Seidlmayer LK; Riediger F; Pagonas N; Nordbeck P; Ritter O; Sasko B
    J Med Case Rep; 2018 Oct; 12(1):298. PubMed ID: 30296944
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In Vivo Excision of HIV-1 Provirus by saCas9 and Multiplex Single-Guide RNAs in Animal Models.
    Yin C; Zhang T; Qu X; Zhang Y; Putatunda R; Xiao X; Li F; Xiao W; Zhao H; Dai S; Qin X; Mo X; Young WB; Khalili K; Hu W
    Mol Ther; 2017 May; 25(5):1168-1186. PubMed ID: 28366764
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CRISPR/Cas9 Gene Editing of RYR2 in Human iPSC-Derived Cardiomyocytes to Probe Ca
    Yamaguchi N; Zhang XH; Morad M
    Methods Mol Biol; 2022; 2573():41-52. PubMed ID: 36040585
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.